TY - JOUR
T1 - Risk factors for ckd progression overview of findings from the cric study
AU - Hannan, Mary
AU - Ansari, Sajid
AU - Meza, Natalie
AU - Anderson, Amanda H.
AU - Srivastava, Anand
AU - Waikar, Sushrut
AU - Charleston, Jeanne
AU - Weir, Matthew R.
AU - Taliercio, Jonathan
AU - Horwitz, Edward
AU - Saunders, Milda R.
AU - Wolfrum, Katherine
AU - Feldman, Harold I.
AU - Lash, James P.
AU - Ricardo, Ana C.
N1 - Funding Information:
The content is solely the responsibility of the author(s) and does not necessarily represent the official views of the NIH. The views expressed here do not necessarily reflect the views of the Robert Wood Johnson Foundation. Funding for the CRIC Study was obtained under a cooperative agreement from the NIDDK under grants U01DK060990, U01DK060984, U01DK061022, U01DK061021, U01DK061028, U01DK060980, U01DK060963, U01DK060902, and U24DK060990. In addition, this work was supported in part by: the Perelman School of Medicine at the University of Pennsylvania Clinical and Translational Science Award NIH/NCATS UL1TR000003, Johns Hopkins University UL1 TR-000424, University of Maryland GCRC M01 RR-16500, Clinical and Translational Science Collaborative of Cleveland, UL1TR000439 from the National Center for Advancing Translational Sciences (NCATS) component of the National Institutes of Health and NIH roadmap for Medical Research, Michigan Institute for Clinical and Health Research (MICHR) UL1TR000433, University of Illinois at Chicago CTSA UL1RR029879, Tulane COBRE for Clinical and Translational Research in Cardiometabolic Diseases P20 GM109036, Kaiser Permanente NIH/NCRR UCSF-CTSI UL1 RR-024131, Department of Internal Medicine, University of New Mexico School of Medicine Albuquerque, NM R01DK119199. M. Hannan has received National Heart, Lung, and Blood Institute award T32HL134634 as a T32 Postdoctoral Fellow. J. Lash is funded by NIDDK grants K24DK092290 and R01DK072231-91. A. Ricardo is funded by NIDDK grant R01DK118736. A. Srivastava is funded by NIDDK grant K23DK120811.
Funding Information:
Funding for the CRIC Study was obtained under a cooperative agreement from the NIDDK under grants U01DK060990, U01DK060984, U01DK061022, U01DK061021, U01DK061028, U01DK060980, U01DK060963, U01DK060902, and U24DK060990. In addition, this work was supported in part by: the Perelman School of Medicine at the University of Pennsylvania Clinical and Translational Science Award NIH/NCATS UL1TR000003, Johns Hopkins University UL1 TR-000424, University of Maryland GCRC M01 RR-16500, Clinical and Translational Science Collaborative of Cleveland, UL1TR000439 from the National Center for Advancing Translational Sciences (NCATS) component of the National Institutes of Health and NIH roadmap for Medical Research, Michigan Institute for Clinical and Health Research (MICHR) UL1TR000433, University of Illinois at Chicago CTSA UL1RR029879, Tulane COBRE for Clinical and Translational Research in Cardiometabolic Diseases P20 GM109036, Kaiser Per-manente NIH/NCRR UCSF-CTSI UL1 RR-024131, Department of Internal Medicine, University of New Mexico School of Medicine Albuquerque, NM R01DK119199. M. Hannan has received National Heart, Lung, and Blood Institute award T32HL134634 as a T32 Postdoctoral Fellow. J. Lash is funded by NIDDK grants K24DK092290 and R01DK072231-91. A. Ricardo is funded by NIDDK grant R01DK118736. A. Srivastava is funded by NIDDK grant K23DK120811.
Funding Information:
A. Anderson reports receiving grants from NIH/NIDDK during the conduct of the study; and personal fees from Kyowa Hakko Kirin, outside the submitted work. H. Feldman reports receiving grants from NIH/NIDDK during the conduct of the study. He also reports consulting for Kyowa Hakko Kirin Co., Ltd. since January 2016 and serving as editor-in-chief of American Journal of Kidney Disease since January 2017, outside the submitted work. M. Hannan is a Robert Wood Johnson Foundation Future of Nursing Scholar Postdoctoral Fellow. E. Horwitz is an employee of MetroHealth MedicalCenter.J.Lashreportsreceiving grantsfromNIHduring the conduct of the study. N. Meza reports receiving grants from NIDDK during the conduct of the study. A. Ricardo reports receiving grants from NIH during the conduct of the study. M. Saunders reports receiving grants from NIH NIDDK during the conduct of the study. A.SrivastavareportsreceivingpersonalfeesfromAstraZeneca,CVS Caremark, and Horizon Pharma PLC, outside the submitted work. J. Taliercio reports employment at Glickman Urological and Kidney Institute, Cleveland Clinic. S. Waikar reports receiving an investigator-initiated grant from Allena Pharmaceuticals and personal fees for serving on academic steering committee for phase 3 trials of a drug to treat hyperoxaluria; personal fees from Barron and Budd (versus Fresenius)forbeinganexpertwitnessonlitigationagainstFreseniusfor Granuflo; personal fees from Bunch and James for being an expert witness on litigation related to mercury exposure; personal fees from Cerus for being a consultant on a device for AKI prevention; personal fees from CVS for consulting on clinical programs; personal fees from GE Healthcare as expert witness on litigation related to Omniscan and nephrogenic systemic fibrosis; personal fees from GlaxoSmithKline for serving on steering committee for phase 3 trials of dapradustat (hypoxia-inducible factor stabilizer for anemia of CKD); personal fees from HarvardClinicalResearchInstitute(alsoknownasBaim)forservingon clinical end-points adjudication committees; personal fees from Kantum Pharma for serving on a scientific advisory board; personal feesfromJNJforspeakingatameeting;personalfeesfromMallinckrodt for serving on an expert panel meeting; personal fees from Mass Medical International for consulting on global nephrology; personal fees from Pfizer for for being a consultant on litigation related to statins and diabetes mellitus; personal fees from Public Health Advocacy InstituteasanexpertwitnessagainstPhilipMorrisforcisplatin-induced lung injury from smoking; personal fees from Roth Capital Partners for speaking to a group of investors interested in learning about oxalate-lowering therapies; personal fees from Strataca for advisory about design of trials for a device for AKI; personal fees from Takeda for servingonasteeringcommitteeforphase4trialonfebuxostat;personal fees from Venbio for speaking to a small group of investors about therapies for CKD; and personal fees from Wolters Kluewer for UpToDate editing; outside the submitted work. M. Weir reports receiving grants from NIDDK-CRIC during the conduct of the study. He also reports receiving personal fees from Boehringer-Ingelheim, Janssen,and MSDforserving onscientific advisory boards; personal fees from Boston Scientific for serving on steering committee; and personal fees from Relypsa/Vifor for serving on the steering committee/advisory board; outside the submitted work. K. Wolfrum reports receiving grants from NIH/NIDDK, which funded the study through which this data were collected. The funds from these grants, through employment at the University of Pennsylvania while working on the CRIC study, finance her salary. All remaining authors have nothing to disclose.
Publisher Copyright:
© 2021 by the American Society of Nephrology.
PY - 2021
Y1 - 2021
N2 - The Chronic Renal Insufficiency Cohort (CRIC) Study is an ongoing, multicenter, longitudinal study of nearly 5500 adults with CKD in the United States. Over the past 10 years, the CRIC Study has made significant contributions to the understanding of factors associated with CKD progression. This review summarizes findings from longitudinal studies evaluating risk factors associated with CKD progression in the CRIC Study, grouped into the following six thematic categories: (1) sociodemographic and economic (sex, race/ethnicity, and nephrology care); (2) behavioral (healthy lifestyle, diet, and sleep); (3) genetic (apoL1, genome-wide association study, and renin-angiotensin-aldosterone system pathway genes); (4) cardiovascular (atrial fibrillation, hypertension, and vascular stiffness); (5) metabolic (fibroblast growth factor 23 and urinary oxalate); and (6) novel factors (AKI and biomarkers of kidney injury). Additionally, we highlight areas where future research is needed, and opportunities for interdisciplinary collaboration.
AB - The Chronic Renal Insufficiency Cohort (CRIC) Study is an ongoing, multicenter, longitudinal study of nearly 5500 adults with CKD in the United States. Over the past 10 years, the CRIC Study has made significant contributions to the understanding of factors associated with CKD progression. This review summarizes findings from longitudinal studies evaluating risk factors associated with CKD progression in the CRIC Study, grouped into the following six thematic categories: (1) sociodemographic and economic (sex, race/ethnicity, and nephrology care); (2) behavioral (healthy lifestyle, diet, and sleep); (3) genetic (apoL1, genome-wide association study, and renin-angiotensin-aldosterone system pathway genes); (4) cardiovascular (atrial fibrillation, hypertension, and vascular stiffness); (5) metabolic (fibroblast growth factor 23 and urinary oxalate); and (6) novel factors (AKI and biomarkers of kidney injury). Additionally, we highlight areas where future research is needed, and opportunities for interdisciplinary collaboration.
UR - http://www.scopus.com/inward/record.url?scp=85104048064&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85104048064&partnerID=8YFLogxK
U2 - 10.2215/CJN.07830520
DO - 10.2215/CJN.07830520
M3 - Article
C2 - 33177074
AN - SCOPUS:85104048064
SN - 1555-9041
VL - 16
SP - 648
EP - 659
JO - Clinical journal of the American Society of Nephrology : CJASN
JF - Clinical journal of the American Society of Nephrology : CJASN
IS - 4
ER -
